Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 16.02 USD | -0.19% | -14.19% | +73.19% | |
Financials (USD)
| Sales 2023 * | - | Sales 2024 * | - | Capitalization | 686 M |
|---|---|---|---|---|---|
| Net income 2023 * | -64.00 M | Net income 2024 * | -82.00 M | EV / Sales 2023 * | - |
| Net cash position 2023 * | 156 M | Net cash position 2024 * | 183 M | EV / Sales 2024 * | - |
| P/E ratio 2023 * | -10,1x | P/E ratio 2024 * | -9,27x | Employees | 93 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 93.82% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.19% | ||
| 1 week | -14.19% | ||
| Current month | -0.19% | ||
| 1 month | +8.61% | ||
| 3 months | +20.27% | ||
| 6 months | +43.29% | ||
| Current year | +73.19% |
1 week
9.55
19.22
1 month
9.5519.22
Current year
5.8819.34
1 year
4.4319.34
3 years
0.5919.34
5 years
0.5919.63
10 years
0.5919.63
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 2016 | |
Anup Marda
DFI | Director of Finance/CFO | 45 | 2018 |
| Compliance Officer | - | 2019 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 67 | 2019 | |
| Chief Executive Officer | 61 | 2016 | |
Mark Simon
BRD | Director/Board Member | 61 | 2018 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.76% | 594 M€ | +7.04% | ||
| 0.10% | 678 M€ | -2.75% | ||
| 0.09% | 49 M€ | +10.01% | - | |
| 0.03% | 620 M€ | +8.31% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-01 | 16.02 | -0.19% | 1,269,362 |
| 23-11-30 | 16.05 | +15.63% | 2,414,781 |
| 23-11-29 | 13.88 | +1.39% | 3,693,293 |
| 23-11-28 | 13.69 | -26.79% | 15,381,930 |
| 23-11-27 | 18.70 | +0.16% | 544,085 |
Delayed Quote Nasdaq, December 01, 2023 at 04:00 pm EST
More quotes
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell for the treatment of patients with autoimmune diseases. Its CABA platform encompasses two approaches: chimeric antigen receptor T cells for autoimmunity (CARTA) and chimeric autoantibody receptor T cells (CAART). Its product candidates include CABA-201, DSG3-CAART, DSG3/1-CAART, MuSK-CAART and PLA2R-CAART. Its lead product candidate, CABA-201, is designed to achieve transient depletion of all CD19-positive B cells following a single infusion, allowing for the elimination disease-causing B cells with subsequent repopulation by naive healthy B cells. Its lead product candidate for the CAART strategy, DSG3-CAART, is designed to enable specific cytotoxicity toward B cells autoreactive to DSG3. Its next PV product candidate, DSG3/1-CAART, is being designed to target DSG3 and/or DSG1 autoreactive B cell receptors on pathogenic B cells that cause mcPV.
Calendar
2024-03-13
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
16.02USD
Average target price
32.00USD
Spread / Average Target
+99.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +73.19% | 686 M $ | |
| +21.60% | 90 488 M $ | |
| +12.94% | 86 658 M $ | |
| +2.47% | 34 551 M $ | |
| +19.81% | 26 777 M $ | |
| -33.83% | 23 629 M $ | |
| -26.62% | 20 547 M $ | |
| -14.75% | 19 529 M $ | |
| -1.94% | 11 507 M $ | |
| +20.17% | 10 906 M $ |
